Ferring Pharmaceuticals Breakfast Symposium
Friday 2 December 2011
0700 – 0820
Melbourne Convention Centre
Level 2, Room 210
Presenter: Dr Joan-Carles Arce, MD, PhD,Vice President,
Clinical Development-Reproductive Health Ferring Pharmaceuticals,
Copenhagen, Denmark
Title: Evidence at Current Clinical Standards
Presentation:
Gonadotrophin preparations containing FSH and LH activity provide a differentiated pharmacokinetic/pharmacodynamic profile compared with those containing only FSH activity including differences in follicular development, ovarian response, embryo quality, endocrine profile and endometrial profile.
The impact of different gonadotrophins on treatment outcome has been explored in the long GnRH agonist protocol in several randomised controlled trials (RCTs) and recent meta-analyses demonstrate the use of menotrophins for controlled ovarian stimulation provide higher ongoing pregnancy/live birth rates than rFSH.
This presentation will include data comparing the efficacy and safety of HP-hMG (MENOPUR) and rFSH in a large randomised controlled trial that incorporates new trends in clinical practice including GnRH antagonist down-regulation, lower starting gonadotrophin doses, compulsory single embryo transfer at the blastocyst stage for all patients in the fresh cycle as well as in the subsequent frozen embryo replacement (vitrified blastocysts) in natural cycles (Nyboe Andersen et al. 2011).
Download a PDF version of the Ferring Pharmaceuticals Sympsium Invitation. [PDF 110KB]